Abstract
The mammalian bombesin (BB)-like peptide gastrin-releasing peptide (GRP) stimulates cell proliferation, displays a range of neuroendocrine activities, and acts as a growth factor in the pathogenesis of several types of human cancer. Several lines of evidence have indicated that GRP and its receptor (GRPR) might also be involved in the neurochemical alterations associated with psychiatric and neurological disorders. GRP and GRPR are distributed throughout the mammalian central nervous system (CNS). Altered levels of BB-like peptides have been found in the CNS of patients with schizophrenia and Parkinsons disease. Dysfunctions in GRPR-induced cellular calcium signaling have been reported in fibroblasts from patients with Alzheimers disease. A translocation in the GRPR gene has been associated with autism. Pharmacological and genetic studies in rodents have shown that GRPRs in brain areas such as the dorsal hippocampus and amygdala are importantly involved in regulating synaptic plasticity and aspects of behavior that might be altered in disorders such as anxiety, schizophrenia, depression, autism and dementia. Behaviors modulated by the GRPR in rodents include grooming, food intake, stereotypy, social behavior, and emotionally-motivated learning and memory. Together, these findings support the view that the GRPR should be considered a therapeutic target for a subset of CNS diseases.
Keywords: Bombesin-like peptides, gastrin-releasing peptide receptor, synaptic plasticity, memory, dementia, schizophrenia, autism, anxiety disorders
CNS & Neurological Disorders - Drug Targets
Title: Gastrin-Releasing Peptide Receptor as a Molecular Target for Psychiatric and Neurological Disorders
Volume: 5 Issue: 2
Author(s): G. Schwartsmann, J. A.P. Henriques and R. Roesler
Affiliation:
Keywords: Bombesin-like peptides, gastrin-releasing peptide receptor, synaptic plasticity, memory, dementia, schizophrenia, autism, anxiety disorders
Abstract: The mammalian bombesin (BB)-like peptide gastrin-releasing peptide (GRP) stimulates cell proliferation, displays a range of neuroendocrine activities, and acts as a growth factor in the pathogenesis of several types of human cancer. Several lines of evidence have indicated that GRP and its receptor (GRPR) might also be involved in the neurochemical alterations associated with psychiatric and neurological disorders. GRP and GRPR are distributed throughout the mammalian central nervous system (CNS). Altered levels of BB-like peptides have been found in the CNS of patients with schizophrenia and Parkinsons disease. Dysfunctions in GRPR-induced cellular calcium signaling have been reported in fibroblasts from patients with Alzheimers disease. A translocation in the GRPR gene has been associated with autism. Pharmacological and genetic studies in rodents have shown that GRPRs in brain areas such as the dorsal hippocampus and amygdala are importantly involved in regulating synaptic plasticity and aspects of behavior that might be altered in disorders such as anxiety, schizophrenia, depression, autism and dementia. Behaviors modulated by the GRPR in rodents include grooming, food intake, stereotypy, social behavior, and emotionally-motivated learning and memory. Together, these findings support the view that the GRPR should be considered a therapeutic target for a subset of CNS diseases.
Export Options
About this article
Cite this article as:
Schwartsmann G., Henriques A.P. J. and Roesler R., Gastrin-Releasing Peptide Receptor as a Molecular Target for Psychiatric and Neurological Disorders, CNS & Neurological Disorders - Drug Targets 2006; 5 (2) . https://dx.doi.org/10.2174/187152706776359673
DOI https://dx.doi.org/10.2174/187152706776359673 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cholinesterases and Cholinesterase Inhibitors
Current Enzyme Inhibition An fMRI Stroop Task Study of Prefrontal Cortical Function in Normal Aging, Mild Cognitive Impairment, and Alzheimers Disease
Current Alzheimer Research Evaluating High-Dose Rivastigmine Patch in Severe Alzheimer’s Disease: Analyses with Concomitant Memantine Usage as a Factor
Current Alzheimer Research Antioxidative Effects of Rhodiola Genus: Phytochemistry and Pharmacological Mechanisms against the Diseases
Current Topics in Medicinal Chemistry Recent Developments in Natural and Synthetic Drug Research for Alzheimers Disease
Letters in Drug Design & Discovery The Role of Nuclear Medicine in Vascular Dementia
Vascular Disease Prevention (Discontinued) A Review on Biological Activities and Chemical Synthesis of Hydrazide Derivatives
Current Medicinal Chemistry Development of a Triggered Nocturnal Blood Pressure Monitoring which Detects Nighttime Blood Pressure Surges in Sleep Apnea Syndrome
Current Hypertension Reviews Intranasal Insulin Prevents Anesthesia-induced Cognitive Impairments in Aged Mice
Current Alzheimer Research Editorial (An Idea Whose Time Has Come? An African Foresight Observatory on Genomics Medicine and Data-Intensive Global Science)
Current Pharmacogenomics and Personalized Medicine Characterization of the Early CNS Stress Biomarkers and Profiles Associated with Neuropsychiatric Diseases
Current Genomics The Role of Atypical Antipsychotic Agents in the Treatment of Schizophrenia and Schizoaffective Disorders in the Elderly
Current Drug Safety A Multicenter, Double-Blind, Placebo-Controlled Trial of the PDE9A Inhibitor, PF-04447943, in Alzheimer's Disease
Current Alzheimer Research Next Steps in Alzheimers Disease Research: Interaction between Epidemiology and Basic Science
Current Alzheimer Research Recent Advances in the Imaging of Programmed Cell Death
Current Pharmaceutical Design Sundowning Syndrome: A Possible Marker of Frailty in Alzheimer’s Disease?
CNS & Neurological Disorders - Drug Targets Definition of Genes and Paths Involved in Alzheimers Disease: Using Gene Expression Profiles and Chemical Genetics at the Mouse Brain Level
Current Genomics Alzheimer’s Disease-related Biomarkers in Aging Adults with Down Syndrome: Systematic Review
Current Psychiatry Research and Reviews APOE Genotypes and Brain Imaging Classes in Normal Cognition, Mild Cognitive Impairment, and Alzheimer’s Disease: A Longitudinal Study
Current Alzheimer Research Genetic Engineering of AAV Capsid Gene for Gene Therapy Application
Current Gene Therapy